Evidence map›Paper›PMID 37242686›Full record

ArticlePharmaceutics2023

Real-Time Monitoring Platform for Ocular Drug Delivery.

Sahar Awwad, Nkiruka Ibeanu, Tianyang Liu, Angeliki Velentza-Almpani, Nerisha Chouhan, Stavros Vlatakis, Peng Tee Khaw, Steve Brocchini, Yann Bouremel

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Special Issue "Antimicrobial Biomaterials: Recent Progress".International journal of molecular sciences · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sahar AwwadOptceutics Ltd., 28a Menelik Road, London NW2 3RP, UK.ORCID 0000-0002-4430-2508
Nkiruka IbeanuOptceutics Ltd., 28a Menelik Road, London NW2 3RP, UK.ORCID 0000-0001-5105-025X
Tianyang LiuOptceutics Ltd., 28a Menelik Road, London NW2 3RP, UK.
Angeliki Velentza-AlmpaniOptceutics Ltd., 28a Menelik Road, London NW2 3RP, UK.
Nerisha ChouhanOptceutics Ltd., 28a Menelik Road, London NW2 3RP, UK.
Stavros VlatakisOptceutics Ltd., 28a Menelik Road, London NW2 3RP, UK.ORCID 0000-0002-8005-6105
Peng Tee KhawOptceutics Ltd., 28a Menelik Road, London NW2 3RP, UK.
Steve BrocchiniOptceutics Ltd., 28a Menelik Road, London NW2 3RP, UK.
Yann BouremelOptceutics Ltd., 28a Menelik Road, London NW2 3RP, UK.ORCID 0000-0003-1852-872X
Moorfields Eye Hospital NHS Foundation Trust · GBUniversity College London · GB

Funding

Innovate UK 41536
6 · The paper itself

Abstract

Real-time measurement is important in modern dissolution testing to aid in parallel drug characterisation and quality control (QC). The development of a real-time monitoring platform (microfluidic system, a novel eye movement platform with temperature sensors and accelerometers and a concentration probe setup) in conjunction with an in vitro model of the human eye (PK-Eye™) is reported. The importance of surface membrane permeability when modelling the PK-Eye™ was determined with a "pursing model" (a simplified setup of the hyaloid membrane). Parallel microfluidic control of PK-Eye™ models from a single source of pressure was performed with a ratio of 1:6 (pressure source:models) demonstrating scalability and reproducibility of pressure-flow data. Pore size and exposed surface area helped obtain a physiological range of intraocular pressure (IOP) within the models, demonstrating the need to reproduce in vitro dimensions as closely as possible to the real eye. Variation of aqueous humour flow rate throughout the day was demonstrated with a developed circadian rhythm program. Capabilities of different eye movements were programmed and achieved with an in-house eye movement platform. A concentration probe recorded the real-time concentration monitoring of injected albumin-conjugated Alexa Fluor 488 (Alexa albumin), which displayed constant release profiles. These results demonstrate the possibility of real-time monitoring of a pharmaceutical model for preclinical testing of ocular formulations.

Indexed as

automationconcentration probesmicrofluidicsocularophthalmologypharmaceutical testingreal-time monitoringsaccades

Identifiers

PMID37242686
PMCPMC10220597
OpenAlexW4378515172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.